Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.
about
Bioavailability through PepT1: the role of computer modelling in intelligent drug design.The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stabilityUSP18 Sensitivity of Peptide Transporters PEPT1 and PEPT2.Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease.Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenatesImpact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice.Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery.The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.Hijacking solute carriers for proton-coupled drug transport.Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach.Addition of amino acid moieties to lapatinib increases the anti-cancer effect via amino acid transporters.Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.Enhanced anticancer activity of glutamate prodrugs of all-trans retinoic acid.Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.Effect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2.Dipeptidyl peptidase IV-activated prodrugs of anti-varicella zoster virus bicyclic nucleoside analogues containing different self-cleavage spacer systems.Modern prodrug design for targeted oral drug delivery.Amino Acids in the Development of ProdrugsThiodipeptides targeting the intestinal oligopeptide transporter as a general approach to improving oral drug delivery
P2860
Q33549909-6B1D7DAA-6E8C-4682-8914-BEFCADB26D01Q34570055-ACD9278B-FD35-4E58-93BE-3EBA4E3BCB4FQ35654199-E8F6ACFA-9E97-47A0-A481-C134B9BCF091Q35831312-30920DAD-9A38-47A8-8841-96067A0CEBECQ35849969-4971CAF5-B0B4-4CE3-8A11-C672BA6645F5Q36631747-DCACF8B3-747D-4A8A-88E4-10BCD6879967Q37193116-F88371E4-97D5-4702-947D-5DC142C4A0E1Q37300767-655EFD10-6F3A-4117-8F77-A42F80E22614Q37617635-2E750530-CCA4-4E91-9B0F-F54FB1EBE52EQ37824123-F29DC5E7-6266-4D3F-9AD5-568562BB5F45Q38019048-E653EF8C-38A4-4842-BB8A-CD8740FE0F06Q39073102-C0F7A2EB-1D85-4277-9E8F-BDB8F2C68B90Q39255478-2CB5E459-0E35-4334-A531-56E9DF3166BCQ39373589-2B178996-4DCC-4667-B0C0-C96D845A134CQ39525005-AF0E523E-03E8-4E67-813C-499E3B715164Q39568178-81E62473-1F32-4BFA-9D28-7059C946DE0DQ39789942-8C8FE830-CD64-404A-B6E7-8416C895D651Q43247402-C0DF6CA7-443E-4C4B-A54C-E5D5827957BFQ44028421-42467EBF-6F17-4038-A9A4-4EE43C18D950Q45355550-261EBA43-168B-4041-B715-B4DB4E5A5AE5Q51042522-56AA3D09-5574-4621-837A-153B4BCBF7D1Q58696356-C34BF08B-29B2-4734-90DA-1C042F5B4DDDQ58800074-33287C4C-E249-4673-ACF1-9753FBDDCCEB
P2860
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Enhanced cancer cell growth in ...... inity and metabolic stability.
@en
Enhanced cancer cell growth in ...... inity and metabolic stability.
@nl
type
label
Enhanced cancer cell growth in ...... inity and metabolic stability.
@en
Enhanced cancer cell growth in ...... inity and metabolic stability.
@nl
prefLabel
Enhanced cancer cell growth in ...... inity and metabolic stability.
@en
Enhanced cancer cell growth in ...... inity and metabolic stability.
@nl
P2093
P2860
P356
P1476
Enhanced cancer cell growth in ...... inity and metabolic stability.
@en
P2093
Gordon L Amidon
John M Hilfinger
Yasuhiro Tsume
P2860
P304
P356
10.1021/MP800008C
P407
P577
2008-07-25T00:00:00Z